Lv1
30 积分 2022-12-07 加入
Efficacy and safety of re-challenging 160 mg furmonertinib for advanced NSCLC after resistance to third-generation EGFR-TKIs targeted agents: A real-world study
2个月前
已完结
Thermal Ablation, Embolization, and Selective Internal Radiation Therapy Combined with Checkpoint Inhibitor Cancer Immunotherapy: Safety Analysis
3个月前
已完结
Targeting KRASG12C in Non-Small-Cell Lung Cancer: Current Standards and Developments
5个月前
已完结
Rare SMARCA4-deficient thoracic tumor: Insights into molecular characterization and optimal therapeutics methods
5个月前
已完结
Tackling Osimertinib Resistance in EGFR-Mutant Non–Small Cell Lung Cancer
7个月前
已完结
Artificial intelligence for predictive biomarker discovery in immuno-oncology: a systematic review
7个月前
已完结
Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France: a phase 3, open-label, randomised controlled trial
8个月前
已完结
Evaluation of first-line and salvage therapies for unresectable malignant mesothelioma: A systematic review and network meta-analysis
8个月前
已完结
皖公网安备34019202002308
